Clinical Trials Browser

Phase 2 × Trastuzumab × Head & Neck × Clear all

NCT05408845 2026-01-14

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT06130007 2023-11-13

B2023-153

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT00004163 2017-04-18

Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer

Phase 2 Completed

Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT00126607 2013-02-28

Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Phase 2 Terminated

Salivary Gland Neoplasms